Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta (PIK3CD, also known as p110δ) is a class IA phosphoinositide 3-kinase (PI3K) catalytic isoform predominantly expressed in hematopoietic cells, particularly leukocytes. It plays a critical, non-redundant role in immune cell development, signaling, and function, acting downstream of antigen receptors (BCR and TCR), cytokine receptors, and chemokine receptors. Upon activation, PIK3CD phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3), which recruits and activates downstream effectors like AKT and mTOR to promote cell survival, proliferation, and migration. Dysregulation of PIK3CD is heavily implicated in human diseases; gain-of-function mutations in the PIK3CD gene cause Activated PI3K-delta Syndrome (APDS), a primary immunodeficiency characterized by lymphoproliferation, recurrent infections, and increased risk of lymphoma. Additionally, hyperactivation of PI3Kδ signaling is a hallmark of various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and follicular lymphoma. Consequently, PIK3CD has become a major therapeutic target, with selective inhibitors like idelalisib and leniolisib approved for treating hematological cancers and APDS, respectively. However, therapeutic targeting of PI3Kδ is often limited by significant immune-mediated toxicities, such as colitis, hepatotoxicity, and pneumonitis.
Inhibition of phosphoinositide 3-kinase delta (PI3Kδ) catalytic activity, preventing the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3), thereby blocking downstream AKT/mTOR signaling pathways.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta (PIK3CD) (PIK3CD).